1. Forbes A and Marie I. Rheumatology (Oxford) 2009;48:iii36–9.
2. Distler O et al. N Engl J Med 2019;380:2518–28.

The SENSCIS trial was funded by Boehringer Ingelheim. Editorial and formatting assistance, supported financially by Boehringer Ingelheim, was provided by Elizabeth Ng and Wendy Morris of FleishmanHillard Fishburn, London, UK during preparation of this poster. The authors were fully responsible for all content and editorial decisions, were involved at all stages of poster development and have approved the final version. Boehringer Ingelheim was given the opportunity to review the poster for medical and scientific accuracy as well as intellectual property considerations. The authors received no direct compensation related to the development of this poster. Stéphane Jouneau reports personal fees from Actelion, AIRB, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Chiesi, Galecto, Gilead, GlaxoSmithKline, LVL, Mundipharma, Novartis, Pfizer, Roche, and Savara-Serendex. Christopher P Denton reports grants and personal fees from CSL Behring, GlaxoSmithKline and Inventiva and personal fees from Bayer, Boehringer Ingelheim, Leadiant Biosciences, and Roche.